“…FMR1 silencing results in a lack of fragile X mental retardation protein (FMRP) production leading to abnormal dendritic overgrowth of immature spines [2,3]. The mechanism by which these phenomena occur is unknown, but it is hypothesized to be a consequence of enhanced activity of metabotropic glutamate receptors (mGluR) [4,5]; although, FMRP has also been found to affect additional neurotransmitter case reports [16,17], clinical impressions [12], or open-label trials [18]. Only two double-blind, placebo-controlled clinical trials of psychotropic medication in FXS have been published [19,20].…”